AC Immune SA (ACIU) stock rallied over 0.62% intraday to trade at $3.24 a share on NASDAQ. The stock opened with a gain of 10.20% at $3.24 and touched an intraday high of $3.24, rising 0.62% against the last close of $3.22. The stock went to a low of $3.08 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
AC Immune SA (NASDAQ: ACIU) stock price is $3.24 as of the last check on Thursday, June 23. During the trading session, ACIU stock reached the peak price of $3.24 while $3.08 was the lowest point it dropped to.
The NASDAQ listed ACIU is part of Biotechnology industry that operates in the broader Health Care sector. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Mr. Joerg Hornstein
Chief Financial Officer
Mr. Gautam Maitra Fil. Lic
Head of Regulatory & External Affairs and Sr. Expert
Dr. Maria Pihlgren Ph.D.
Head of Biology
Dr. Andrea Pfeifer Ph.D.
Co-Founder, CEO & Director
ACIU stock traded closed the last session at $3.24, which is $0.02 or 0.62% lower than its previous close of $3.22. ACIU's current trading price is 57.28% lower than its 52-week high of $12.61 where as its distance from 52-week low of 2.06% is -74.31%.
Number of ACIU employees currently stands at -. ACIU operates from Building B, EPFL Innovation Park, Lausanne 1015, Switzerland.
Official Webiste of $ACIU is: https://www.acimmune.com
ACIU stock volume for the day was 45,922 shares while in the previous session number of ACIU shares traded was 45,900 . The average number of ACIU shares traded daily for last 3 months was 93.24 Thousands.
The percentage change in ACIU stock occurred in the recent session was 0.62% while the dollar amount for the price change in ACIU stock was $0.02.
In the recent session, the day high for ACIU stock was $3.24 while the low for ACIU stock touched on the day was $3.08.
The market value of ACIU currently stands at 244.62 Million with its latest stock price at $3.24 and 81.89 Million of its shares outstanding.